JMP keeps ViroPharma at market outperform

ViroPharma Inc. was reiterated at market outperform by JMP Securities analyst Adam Cutler after the company announced the start of one of two phase 3 trials for maribavir in the prevention of cytomegalovirus disease. The trial will be conducted in 500 bone marrow transplant patients at about 80 centers, with enrollment expected to take roughly 18 months. Shares of the Exton, Pa.-based pharmaceutical company were down 24 cents, or 1.93%, at $12.17. (Nasdaq: VPHM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.